MX2017002796A - Tasimelteon para tratar el sindrome de smith-magenis. - Google Patents
Tasimelteon para tratar el sindrome de smith-magenis.Info
- Publication number
- MX2017002796A MX2017002796A MX2017002796A MX2017002796A MX2017002796A MX 2017002796 A MX2017002796 A MX 2017002796A MX 2017002796 A MX2017002796 A MX 2017002796A MX 2017002796 A MX2017002796 A MX 2017002796A MX 2017002796 A MX2017002796 A MX 2017002796A
- Authority
- MX
- Mexico
- Prior art keywords
- smith
- tasimelteon
- treat
- magenis syndrome
- magenis
- Prior art date
Links
- 201000001388 Smith-Magenis syndrome Diseases 0.000 title abstract 3
- PTOIAAWZLUQTIO-GXFFZTMASA-N tasimelteon Chemical compound CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2 PTOIAAWZLUQTIO-GXFFZTMASA-N 0.000 title 1
- 229960000660 tasimelteon Drugs 0.000 title 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Electric Connection Of Electric Components To Printed Circuits (AREA)
- Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
- Processing Of Solid Wastes (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Steroid Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Led Device Packages (AREA)
- Coils Or Transformers For Communication (AREA)
Abstract
Las modalidades de la invención se refieren al tratamiento de alteraciones del sueño en individuos con el Síndrome de Smith - Magenis (SMS).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462044856P | 2014-09-02 | 2014-09-02 | |
| US201562169635P | 2015-06-02 | 2015-06-02 | |
| PCT/US2015/047610 WO2016036619A1 (en) | 2014-09-02 | 2015-08-29 | Tasimelteon for treating smith-magenis syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017002796A true MX2017002796A (es) | 2017-06-09 |
| MX386150B MX386150B (es) | 2025-03-18 |
Family
ID=54147267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002796A MX386150B (es) | 2014-09-02 | 2015-08-29 | Tasimelteon para tratar el síndrome de smith-magenis. |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10179119B2 (es) |
| EP (2) | EP4137129A1 (es) |
| JP (3) | JP6903571B2 (es) |
| KR (2) | KR20170048541A (es) |
| CN (2) | CN116098887A (es) |
| AU (2) | AU2015312252B2 (es) |
| BR (1) | BR112017003644A2 (es) |
| CA (2) | CA3124872A1 (es) |
| DK (1) | DK3188727T3 (es) |
| ES (1) | ES2936833T3 (es) |
| FI (1) | FI3188727T3 (es) |
| HR (1) | HRP20230070T1 (es) |
| HU (1) | HUE061051T2 (es) |
| MX (1) | MX386150B (es) |
| PT (1) | PT3188727T (es) |
| SI (1) | SI3188727T1 (es) |
| WO (1) | WO2016036619A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009538332A (ja) * | 2006-05-22 | 2009-11-05 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | メラトニンアゴニスト治療 |
| SI3188727T1 (sl) * | 2014-09-02 | 2023-03-31 | Vanda Pharmaceuticals Inc. | Tasimelteon za zdravljenje Smith-Magenisovega sindroma |
| CN112074268A (zh) * | 2018-03-04 | 2020-12-11 | 万达制药公司 | 用他司美琼治疗疾病 |
| KR20210060489A (ko) * | 2018-09-12 | 2021-05-26 | 반다 파마슈티칼즈, 인코퍼레이티드. | 수면 또는 수면 후 거동 개선 |
| AU2020400065B2 (en) * | 2019-12-13 | 2025-08-14 | Vanda Pharmaceuticals Inc. | Liquid tasimelteon formulations and methods of use thereof |
| US20230314471A1 (en) | 2020-08-27 | 2023-10-05 | Yokowo Co., Ltd. | Inspection device |
| US20250339398A1 (en) * | 2021-09-14 | 2025-11-06 | Vanda Pharmaceuticals Inc. | Treatment of sleep distrubances in autism spectrum disorder patients |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9711051B (en) | 1996-12-10 | 1999-06-09 | Bristol Myers Squibb Co | Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents |
| WO2005063240A1 (en) | 2003-12-22 | 2005-07-14 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
| US7754902B2 (en) | 2006-05-18 | 2010-07-13 | Vanda Pharmaceuticals, Inc. | Ruthenium(II) catalysts for use in stereoselective cyclopropanations |
| JP2009538332A (ja) | 2006-05-22 | 2009-11-05 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | メラトニンアゴニスト治療 |
| US20080260837A1 (en) | 2007-04-20 | 2008-10-23 | Qpharma, L.L.C. | Physically stable aqueous suspensions of active pharmaceuticals |
| KR100928515B1 (ko) | 2008-04-02 | 2009-11-26 | 주식회사 동부하이텍 | 데이터 수신 장치 |
| EP2453891A1 (en) | 2009-07-16 | 2012-05-23 | Vanda Pharmaceuticals Inc. | Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia |
| RU2631602C2 (ru) * | 2012-01-26 | 2017-09-25 | Ванда Фармасьютиклз Инк. | Лечение нарушений циркадного ритма |
| CN102675268A (zh) * | 2012-05-18 | 2012-09-19 | 济南志合医药科技有限公司 | 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法 |
| US10376487B2 (en) * | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| SI3188727T1 (sl) * | 2014-09-02 | 2023-03-31 | Vanda Pharmaceuticals Inc. | Tasimelteon za zdravljenje Smith-Magenisovega sindroma |
| AU2020400065B2 (en) * | 2019-12-13 | 2025-08-14 | Vanda Pharmaceuticals Inc. | Liquid tasimelteon formulations and methods of use thereof |
-
2015
- 2015-08-29 SI SI201531919T patent/SI3188727T1/sl unknown
- 2015-08-29 EP EP22199492.4A patent/EP4137129A1/en active Pending
- 2015-08-29 BR BR112017003644A patent/BR112017003644A2/pt not_active Application Discontinuation
- 2015-08-29 HR HRP20230070TT patent/HRP20230070T1/hr unknown
- 2015-08-29 CN CN202310255914.1A patent/CN116098887A/zh active Pending
- 2015-08-29 FI FIEP15766274.3T patent/FI3188727T3/fi active
- 2015-08-29 EP EP15766274.3A patent/EP3188727B1/en active Active
- 2015-08-29 DK DK15766274.3T patent/DK3188727T3/da active
- 2015-08-29 WO PCT/US2015/047610 patent/WO2016036619A1/en not_active Ceased
- 2015-08-29 US US15/326,934 patent/US10179119B2/en active Active
- 2015-08-29 AU AU2015312252A patent/AU2015312252B2/en active Active
- 2015-08-29 CA CA3124872A patent/CA3124872A1/en active Pending
- 2015-08-29 CA CA2957588A patent/CA2957588C/en active Active
- 2015-08-29 ES ES15766274T patent/ES2936833T3/es active Active
- 2015-08-29 MX MX2017002796A patent/MX386150B/es unknown
- 2015-08-29 KR KR1020177009052A patent/KR20170048541A/ko not_active Ceased
- 2015-08-29 HU HUE15766274A patent/HUE061051T2/hu unknown
- 2015-08-29 PT PT157662743T patent/PT3188727T/pt unknown
- 2015-08-29 KR KR1020247002426A patent/KR20240015729A/ko active Pending
- 2015-08-29 JP JP2017512287A patent/JP6903571B2/ja active Active
- 2015-08-29 CN CN201580046852.7A patent/CN106604726A/zh active Pending
-
2018
- 2018-12-06 US US16/211,687 patent/US10653665B2/en active Active
-
2020
- 2020-04-14 US US16/848,150 patent/US11266622B2/en active Active
- 2020-06-04 JP JP2020097599A patent/JP7132277B2/ja active Active
- 2020-09-22 AU AU2020239640A patent/AU2020239640B2/en active Active
-
2022
- 2022-01-14 US US17/648,046 patent/US20220133681A1/en not_active Abandoned
- 2022-03-14 JP JP2022039475A patent/JP7252390B2/ja active Active
-
2024
- 2024-05-08 US US18/658,100 patent/US20240293355A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123065T1 (el) | Ανασυνδυασμενα προβιοτικα βακτηριδια | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| BR112017006664A2 (pt) | terapias de combinação | |
| MX2024010175A (es) | Moleculas de anticuerpo contra april y usos de las mismas. | |
| EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| CL2016002123A1 (es) | Nuevo polisacárido y usos del mismo | |
| MX2017002796A (es) | Tasimelteon para tratar el sindrome de smith-magenis. | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| DK3201148T3 (da) | Sammensmeltet telluratglas med forarbejdningstemperaturer på 420ºC | |
| DK3888641T3 (da) | Anvendelse af cannabidiol i behandling af anfald i forbindelse med doose-syndrom | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| LT3882250T (lt) | Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui | |
| CR20160561A (es) | Variantes del anticuerpo anti-factor d y sus usos | |
| MX2015011281A (es) | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| TWD170353S (zh) | 項鍊 | |
| CL2015000873A1 (es) | Métodos para el tratamiento del síndrome de alport. | |
| MX381640B (es) | Metodos y compuestos agonistas de gip. | |
| MX389560B (es) | Enfoque de inmunoterapias de combinación para el tratamiento del cancer. | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CU24407B1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| CL2016000326A1 (es) | Composiciones y método para tratar condiciones asociadas con el complemento | |
| PL3978074T3 (pl) | Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1 | |
| MX374385B (es) | Apilimod para uso en el tratamiento de melanoma. | |
| UY36286A (es) | Tratamientos médicos basados en anamorelina |